Advertisement
Advertisement
U.S. markets close in 2 hours 39 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Annexon, Inc. (ANNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.93-0.19 (-3.13%)
As of 01:21PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close6.12
Open6.08
Bid5.89 x 800
Ask5.94 x 1000
Day's Range5.68 - 6.09
52 Week Range2.06 - 23.61
Volume71,516
Avg. Volume410,254
Market Cap282.302M
Beta (5Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)-3.63
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ANNX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Annexon, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results

    Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations Multiple Clinical Readouts Anticipated throughout 2022 and 2023 Operating Runway into the Second Half of 2025 Following $130 Million Private Placement BRISBANE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoim

  • GlobeNewswire

    Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025

    Proceeds Support Advancement of Broad Pipeline of Novel Complement Product Candidates for Diseases of the Body, Brain and EyeBRISBANE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the closing of its private placement, resulting in gross proceeds of approximately

  • GlobeNewswire

    Annexon Announces $130 Million Private Placement Financing

    BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $130 million, before deducting placement agent fees and other exp

Advertisement
Advertisement